


# Healthcare Breakthrough

L&G Healthcare Breakthrough UCITS ETF



**DISRUPTIVE**  
Technology thematics range

## Key features

Exposure to a basket of specialised healthcare technology and innovation companies

---

Diversification across geography, market cap and sub-sectors

---

Potential for reduced volatility versus investing in individual healthcare technology and innovation stocks

---

Quarterly rebalancing maintains diversification and provides responsiveness to new entrants and market trends

---

UCITS compliant

---



# DISRUPTIVE

Technology thematic range

# Healthcare technology and innovation

The coming waves of innovation in healthcare technology may change not only how medical professionals help people, but what they are capable of doing in the first place.

Advances in robotics will improve surgical outcomes and the digitalisation of the healthcare supply chain will lead to lower costs. But that is only half the story. Next-generation diagnostic tools will be able to identify illnesses much earlier than is currently possible and new genomic and miniaturisation techniques will revolutionise both what can be treated and how efficiently conditions can be managed.

L&G ETF has partnered with ROBO Global®, a well-regarded provider of investable technology indices, to offer investors a liquid, transparent and cost-effective vehicle to access this transformative theme.

## MULTIPLE VECTORS FOR GROWTH

The L&G Healthcare Breakthrough UCITS ETF seeks to capture the value created by these revolutionary technologies being applied to healthcare, one of the most established sectors in the market.

- \$8.7 trillion industry worldwide by 2020<sup>1</sup>
- 18% of US GDP in 2017<sup>2</sup>

## The key drivers of this growth are:

- The global population is aging rapidly and becoming wealthier, which creates an ever-increasing demand for healthcare products.
- Rapid advances in artificial intelligence, electronics, genomics, miniaturisation, advanced simulation, and analytics are revolutionising non-drug-related medical technology capabilities.
- Digitalisation of the healthcare supply chain is leading to lower costs, labour efficiency and the ability to reach a larger, global patient consumer base more effectively.
- Healthcare products historically have been economically inelastic, leading to structural increases in demand with minimal cyclicalities.

Most importantly for investors and society, the greatest gains from healthcare technology and innovation still lie ahead – such as the wider adoption of robot-augmented surgery, early-diagnostic tools, minimally invasive treatments, and many more applications.

These improvements in healthcare technology have the potential to disrupt many existing business models and create high-growth new markets for the most innovative healthcare companies. L&G Healthcare Breakthrough UCITS ETF is designed to identify and own these stocks.

## An ETF prepared for an ever-changing investment theme

<sup>1</sup>Source: Deloitte, 2017    <sup>2</sup>Source: US Centers for Medicare & Medicaid Services, 2018

# Know your healthcare technology and innovation exposure

## PHYSICAL REPLICATION

The L&G Healthcare Breakthrough UCITS ETF uses full physical replication to offer investors direct exposure to the theme.

## INDUSTRY EXPERTISE

We believe the unrivalled expertise of the ROBO Global® advisory board ensures that the ROBO Global® Healthcare Technology and Innovation Index (the index) is able to capture the entire value chain of healthcare technology and innovation.

## GROWTH DIVERSIFIER

The index has a typical market-cap breakdown of 40% in small and mid-caps and 60% in large-caps. It therefore has less than 5% overlap with traditional benchmarks such as the S&P 500 or the MSCI World.

## BROAD GLOBAL EXPOSURE

The modified equal-weighting scheme of the index ensures all companies in the industry are fairly represented. Because we are too early in the theme to confidently identify all of tomorrow's best performers, this approach seeks to maximise exposure to the growth potential while mitigating any company-specific risks in the basket.



## Product information

Fund Name	L&G Healthcare Breakthrough UCITS ETF
Benchmark	ROBO Global® Healthcare Technology and Innovation UCITS Index
Listings and Tickers	London Stock Exchange – DOCT (USD), DOCG (GBP) Deutsche Börse – XMLH (EUR) Borsa Italiana – DOCT (EUR) SIX Swiss Exchange – DOCT (CHF)
ISIN Code	IE00BK5BC677
UCITS Compliant	Yes

Domicile	Ireland
TER (%)	0.49
Base Currency	USD
Replication	Physical – Full replication
Distribution	Accumulating
Issuer	LGIM Managers (Europe) Limited
Promoter/Distributor	Legal & General Investment Management Limited

The value of an investment and any income taken from it is not guaranteed and can go down as well as up. You may not get back the amount you originally invested.

### Secondary Market

The shares of this exchange-traded UCITS fund are publicly admitted to trading on the secondary markets of the stock exchanges detailed in the Product Information table.

ROBO Global's Industry Classification is a forward-looking road map, supported by insights from a dedicated coverage team, to ensure sub-sectors evolve and expand at the right time. The Industry classification is updated on a quarterly basis and managed by the ROBO Global Industry Classification Committee.



GENOMICS



ROBOTICS

LAB PROCESS  
AUTOMATION

DIAGNOSTIC



DATA ANALYTICS

PRECISION  
MEDICINEMEDICAL  
INSTRUMENTS

TELEHEALTH

REGENERATIVE  
MEDICINE

# Index and weighting methodology

## Index methodology

L&G Healthcare Breakthrough UCITS ETF performs fundamental and industry research to establish a classification of disruptive healthcare technologies including medical instruments, diagnostics, robotics, genomics, precision medicine, lab automation, data analytics, regenerative medicine, and telehealth.

Companies involved in the various sectors of the classification are then evaluated for technology and market leadership, as well as revenue and investment exposure, resulting in a composite 'HTEC score'. The ROBO Global® Healthcare Technology and Innovation Index is composed of companies with a high HTEC score that also pass ROBO Global's Environmental, Social and Governance (ESG) policy requirements.

Including more than 80 stocks across 9 subsectors in 15 countries, the index is built to minimise risk by limiting reliance on the largest-cap players, and to capture the growth of rapidly developing healthcare technology companies around the globe.

## Weighting methodology

Index constituents are weighted according to their 'HTEC Score'. Each constituent's weight is calculated by dividing its 'HTEC Score' by the sum of all constituents' 'HTEC Scores'. This process ensures that the index allocates a larger weight to those players that derive a distinct portion of their revenues from the field of healthcare technologies, and which have the potential to grow within this space through innovation and/or market adoption of their products and/or services. The index rebalances quarterly to maintain diversification and remain responsive to market trends and new entrants.

For more information, visit: [ROBOGlobal.com/HTEC](https://ROBOGlobal.com/HTEC)




## Learn more

To learn more about the L&G Healthcare Breakthrough UCITS ETF visit [www.lgimETF.com](https://www.lgimETF.com)

# Index performance

## Historical Backtested Performance Rebased 100 = June 2015



Source: Bloomberg

Annual index performance	2020	2019	2018	2017	2016	2015
ROBO Global Healthcare Technology and Innovation Index TR	16.65%	34.92%	25.25%	39.31%	11.58%	12.34%
MSCI World Net Total Return USD Index	-5.77%	27.67%	-8.71%	22.40%	7.51%	-0.87%

	1 year	3 years	5 years	Volatility	Sharpe Ratio
ROBO Global Healthcare Technology and Innovation Index TR	24.87%	109.87%	214.94%	20.50%	1.20
MSCI World Net Total Return USD Index	2.84%	21.48%	39.59%	16.04%	0.36

All returns, correlations and volatilities are based on data in USD. Dates are from 30 June 2015 to 30 June 2020 unless otherwise stated. Sharpe ratios are based on 5 year annualised returns, 5 year annualised volatility and a risk free rate of 1.2% (average of US 5yr rates over 1 year).

The index was launched on 1 May 2019. In the period prior to that, the index values were simulated and were based on back-tested data. Simulated past performance data does not represent actual performance and should not be interpreted as an indication of actual or future performance.

The value of an investment and any income taken from it is not guaranteed and can go down as well as up; you may not get back the amount you originally invested.

## Important Information

Copyright © 2019 Legal & General. This document is subject to copyright. Any unauthorised use is strictly prohibited. All rights are reserved.

Issued by LGIM Managers (Europe) Limited as management company for this fund. Registered in Ireland No. 609677. Registered Office: 33/34 Sir John Rogerson's Quay, Dublin, 2, Ireland. Authorised and Regulated by the Central Bank of Ireland No. C173733.

GO ETF Solutions LLP has been appointed as the discretionary investment manager for this Fund, it is authorised and regulated by the Financial Conduct Authority No.477266.

Legal & General Investment Management Limited has been appointed promoter and distributor for this Fund and has a MiFID II passport to act in this capacity currently in various European countries, as well as in the UK. Registered in England and Wales No. 02091894. Registered Office: One Coleman Street, London, EC2R 5AA, United Kingdom. Authorised and regulated by the Financial Conduct Authority, No. 119272.

We are a member of the Irish Funds Association.

All features described in this factsheet are those current at the time of publication and may be changed in the future. Nothing in this factsheet should be construed as advice and it is therefore not a recommendation to buy or sell securities. If in doubt about the suitability of this product, you should seek professional advice. Copies of the prospectus, key investor information document, annual and semi-annual reports & accounts are available free of charge on request or at [www.lgimETF.com](http://www.lgimETF.com).


This document is only directed at investors resident in jurisdictions where our funds are registered for sale. It is not an offer or invitation to persons outside of those jurisdictions. We reserve the right to reject any applications from outside of such jurisdictions.

---

## CONTACT US

For further information please contact us:

 0345 070 8684

 [fundsales@lgim.com](mailto:fundsales@lgim.com)

 [lgimETF.com](http://lgimETF.com)

We record and monitor calls. Call charges will vary.